-
METTL14, DHRS4-AS1, and Inflammation in UC
2026-09-22
The reference study identifies a protective METTL14–DHRS4-AS1–miR-206/A3AR regulatory axis in ulcerative colitis models. Its combined cell-based, molecular, and murine evidence suggests that m6A-dependent control of a long non-coding RNA can influence epithelial injury, NF-κB signaling, apoptosis, and intestinal inflammation.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-09-22
The reference study identifies 1-Phenyl-2-Pentanol from Moringa oleifera leaves and shows that it suppresses profibrotic responses in TGF-β1-stimulated human hepatic stellate cells. Its integrated use of marker analysis, proteomics, and molecular docking connects reduced extracellular-matrix signaling with potential inhibition of TGF-β1 and Wnt/β-catenin pathways, while remaining an in vitro finding.
-
Panoramic Hyperspectral Mapping of Cardiac Arrhythmia
2026-09-21
Kowalik and colleagues introduce a multimodal platform that co-registers collagen-sensitive hyperspectral maps of epicardial tissue with optical maps of transmembrane potential across infarcted rat hearts. The study shows how tissue classification can place action-potential duration, premature ventricular contractions, and reentrant activity within a spatially resolved structural context.
-
Chlorpromazine HCl in Endocytosis Assay Design
2026-09-21
Chlorpromazine HCl can serve as a mechanistically informative perturbation in neuropharmacology and cell-based uptake studies. This article explains how to pair its dopamine receptor activity with electrical-stimulation models of nanoparticle endocytosis while separating causal interpretation from assay confounding.
-
CircRHOBTB3–NONO Signaling in Prostate Cancer
2026-09-20
A 2025 Cancer Letters study identifies circRHOBTB3 as a prostate cancer suppressor that retains NONO in the cytoplasm, reducing MAOA transcription and limiting proliferation and metastasis. The work also links circRNA production to SRSF9-mediated regulation of Alu elements, providing a mechanistic framework for biomarker and pathway studies in metastatic prostate cancer.
-
Chlorpromazine HCl: Mechanism and Assay Use
2026-09-19
Chlorpromazine HCl is a phenothiazine dopamine receptor antagonist used in psychotic disorder research and neuropharmacology studies. Its receptor-binding, neuronal electrophysiology, hypoxia-model, and storage parameters support controlled assay design, but the available nanoparticle endocytosis study does not directly test chlorpromazine.
-
WEHI-539: Mapping BCL-XL-Dependent Apoptosis
2026-09-18
WEHI-539 is a selective BCL-XL inhibitor for resolving how mitochondrial apoptotic dependence shapes drug response. This guide connects biochemical potency with BAK-dependent cell death, cancer stem cell sensitization, and practical assay design.
-
FITC Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-18
Translate O-GlcNAcylation findings in porcine oocytes into practical immunofluorescence and flow cytometry workflows with a sensitive fluorescein-conjugated secondary antibody. This guide emphasizes controls, quantitative staining choices, storage, and troubleshooting for detecting mouse IgG primary antibodies across cytoskeletal, mitochondrial, oxidative-stress, and autophagy-related assays.
-
Hematoxylin and Eosin Staining Kit Protocol
2026-09-17
The Hematoxylin and Eosin Staining Kit (SKU K1142) provides ready-to-use hematoxylin and eosin solutions for tissue morphology visualization in paraffin, frozen, and cytological samples. It supports research workflows but requires local protocol optimization and is not intended for diagnostic or medical use.
-
Protein A/G Magnetic Co-IP/IP Kit for RNF8–DAPK1
2026-09-17
Apply magnetic immunoprecipitation to preserve and interrogate protein complexes in ischemic-stroke models, including the RNF8–DAPK1 relationship highlighted in recent research. The workflow also supports antibody cleanup, SDS-PAGE, and mass spectrometry with less manual handling than conventional agarose formats.
-
Caged Bioluminescent Probe for the Immunoproteasome
2026-09-16
Loy and Trader present a protocol for synthesizing and applying a cleavable, bioluminescent activity-based probe selective for the immunoproteasome β5i subunit. By combining an iCP-recognition peptide with aminoluciferin and a plate-reader-compatible luminescence assay, the study expands options for monitoring immunoproteasome activity in cells and tissue-mimetic settings.
-
AP2-M Links Gene Regulation to Babesia Replication
2026-09-16
The reference study identifies AP2-M as a chromatin-associated regulator of Babesia sp. Xinjiang asexual development, connecting promoter binding with red blood cell invasion, merozoite morphology, and cell-cycle progression. By integrating Cut&Tag, gene disruption, transcriptomics, proteomics, and single-cell RNA sequencing, it provides a framework for distinguishing direct regulatory targets from downstream developmental effects.
-
Protein A/G Magnetic Co-IP/IP Kit Guide
2026-09-15
Learn how Protein A/G Magnetic Co-IP/IP Kit K1309 can improve protein-complex validation when viability, proliferation, or cytotoxicity results require mechanistic support. This scenario-based guide covers compatibility, protocol control, interpretation, and practical product-selection criteria.
-
SVP3 Hetero-Galactan and Hypolipidemia
2026-09-15
The reference study characterizes SVP3, a neutral hetero-galactan purified from Sanghuangporus vaninii, and links its lipid-lowering activity to coordinated changes in gut microbiota, serum metabolites, and hepatic proteins. In a hyperlipidemic mouse model, SVP3 reduced circulating lipid measures, adipose expansion, and hepatic lipid injury while implicating the TLR4/NF-κB inflammatory pathway.
-
G-15: A Precision Lens on GPR30 Signaling
2026-09-14
G-15 is more than a selective G protein-coupled estrogen receptor antagonist: it is a mechanistic tool for separating GPR30-dependent estrogen signaling from classical ERα and ERβ activity. This article connects receptor pharmacology with immune-function research, assay design, translational judgment, and strategic use of pathway-level evidence.